-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on Amrize, Lowers Price Target to $54

Benzinga·08/12/2026 16:18:46
Listen to the news
Stephens & Co. analyst Trey Grooms maintains Amrize (NYSE:AMRZ) with a Overweight and lowers the price target from $65 to $54.